EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. The company's products in pipeline include EG-Mirotin, which has completed Phase IIa clinical trial for the treatment of diabetic retinopathy; EG-Decorin that completed Phase II clinical trial to treat pressure ulcers and wound healing; EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury; EG-TB, a preclinical product for tuberculosis vaccine; and EG-HPV that has completed Phase I clinical trial for the treatment of cervical cancer. It also offers EG-Vac for the treatment of immune adjuvant; EG-COVID that is in phase I clinical trial for the treatment of covid; and EG-HZ, which has completes phase I trials for the treatment of herpes zoster. In addition, the company provides vitalDB for beautiful vitality. EyeGene Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
| 2835 | |
| 2830 | |
| - | |
| 2920 | |
| 2830 | |
| 2430-4895 | |
| 77 711 M | |
| 27 030 K | |
| 2 841 M | |
| -109.5805 | |
| 1.535 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Vancouver, British Columbia--(Newsfile Corp. - May 3, 2022) - Flying Nickel Mining Corp. (TSXV: FLYN) (OTC Pink: FLYNF) ("Flying Nickel" or the "Company") is pleased to announce the appointment of Kat...
European Wax Center, Inc. PLANO, Texas, April 20, 2022 (GLOBE NEWSWIRE) -- European Wax Center, Inc. (NASDAQ: EWCZ), the largest and fastest-growing franchisor and operator of out-of-home waxing serv...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
